(Q43845716)

27 November 2017

Aspergillus: rising frequency of clinical isolation and continued susceptibility to antifungal agents, 1994-1999. (English)

1 reference

27 November 2017

P H Chandrasekar

1

1 reference

27 November 2017

J L Cutright

series ordinal

2

1 reference

27 November 2017

E K Manavathu

series ordinal

3

1 reference

27 November 2017

language of work or name

1 reference

1 December 2001

1 reference

Diagnostic Microbiology and Infectious Disease

27 November 2017

1 reference

27 November 2017

41

1 reference

27 November 2017

4

1 reference

27 November 2017

211-214

1 reference

In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

Fungal infections in cancer patients: an international autopsy survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

Itraconazole resistance in Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

Clinical aspects of fungal infection in organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

A comparative study of the broth micro- and macro-dilution techniques for the determination of the in vitro susceptibility of Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

The spectrum of non-Candida fungal infections following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

A Prospective Study of Infectious Diseases Following Bone Marrow Transplantation: Emergence ofAspergillusandCytomegalovirusas the Major Causes of Mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

Epidemiology ofAspergillusInfections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900295-4

7 January 2021

10.1016/S0732-8893(01)00295-4

Identifiers

DOI

1 reference

27 November 2017

1 reference